



# Leveraging Structured Biological Knowledge for Counterfactual Inference: a Case Study of Viral Pathogenesis

Jeremy Zucker<sup>1\*</sup>, Kaushal Paneri<sup>2\*</sup>, Sara Mohammad-Taheri<sup>3\*</sup>,  
Somya Bhargava<sup>3</sup>, Pallavi Kolambkar<sup>3</sup>, Craig Bakker<sup>1</sup>, Jeremy Teuton<sup>1</sup>, Charles Tapley Hoyt<sup>4</sup>, Kristie Oxford<sup>1</sup>, Robert Ness<sup>5</sup> and Olga Vitek<sup>3†</sup>



**Abstract**—Counterfactual inference is a useful tool for comparing outcomes of interventions on complex systems. It requires us to represent the system in form of a structural causal model, complete with a causal diagram, probabilistic assumptions on exogenous variables, and functional assignments. Specifying such models can be extremely difficult in practice. The process requires substantial domain expertise, and does not scale easily to large systems, multiple systems, or novel system modifications. At the same time, many application domains, such as molecular biology, are rich in structured causal knowledge that is qualitative in nature. This manuscript proposes a general approach for querying a causal biological knowledge graph, and converting the qualitative result into a quantitative structural causal model that can learn from data to answer the question. We demonstrate the feasibility, accuracy and versatility of this approach using two case studies in systems biology. The first demonstrates the appropriateness of the underlying assumptions and the accuracy of the results. The second demonstrates the versatility of the approach by querying a knowledge base for the molecular determinants of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or SARS-CoV-2)-induced cytokine storm, and performing counterfactual inference to estimate the causal effect of medical countermeasures for severely ill patients.

**Keywords**— Biological expression language, structural causal model, counterfactual inference, causal biological knowledge graph, systems biology, SARS-CoV-2

## 1 INTRODUCTION

Each time a cell senses changes in its environment, it marshals a complex choreography of molecular interactions to initiate an appropriate response. When a virus infects the cell, this delicate balance

is disrupted and can result in a cascade of systemic failures leading to disease. In particular, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel pathogen responsible for the COVID-19 pandemic, has a complex etiology that differs in subtle and substantial ways from previously studied viruses. To make informed decisions about the risk that a new pathogen presents, it is imperative to rapidly predict the determinants of pathogenesis and identify potential targets for medical countermeasures. Current solutions for this task include systems biology data-driven models, which correlate biomolecular expression to pathogenicity, but cannot go beyond associations in the data to reason about causes of the disease [1], [2]. Alternatively, hypothesis-driven mathematical models capture causal relations, but are hampered by limited parameter identifiability and predictive power [3], [4].

We argue that counterfactual inference [5] helps bridge the gap between data-driven and hypothesis-driven approaches. It enables questions of the form: “Had we known the eventual outcome of a patient, what would we have done differently?” At the heart of counterfactual inference is a formalism known as a structural causal model (SCM) [5], [6]. It represents prior domain knowledge in terms of causal diagrams, assumes a probability distribution on exogenous variables, and assigns a deterministic function to endogenous variables. SCM are particularly attractive in systems biology, where structured domain knowledge is extracted from the biomedical literature and is readily available through advances in natural language processing [7], [8], [9], large-scale automated assembly systems [10], and semi-automated curation workflows [11]. This knowledge is curated by multiple organizations [12], [13], [14], [15], [16] and stored in structured knowledge bases [17], [18], [19], [20]. It can be brought to bear for answering causal questions regarding SARS-CoV-2.

This manuscript contributes a three-part algorithm that leverages existing structured biological knowledge to answer counterfactual questions about viral pathogenesis. Algorithm 1 formalizes biologically relevant questions as queries to an existing causal knowledge graph. Algorithm 2 converts the query result into a structural causal model. Algorithm 3 operationalizes the counterfactual inference by interrogating the model with the observed data to estimate a causal effect.

We illustrate the benefits of this approach using two case studies. Case study 1 illustrates the increased precision of counterfactual estimates, as compared to the ODE- and SDE-based forward simulation, in a situation with known ground truth mechanisms of data generation. Case study 2 demonstrates the automated construction of an SCM and the value of counterfactual reasoning in novel situations with limited treatment options (as is the case for SARS-CoV-2). It shows that counterfactual inference enables more precise predictions regarding who would be likely to survive without receiving treatment, who would

\*Equal contribution

<sup>1</sup> Pacific Northwest National Laboratory, Richland, WA

<sup>2</sup> Microsoft, Redmond, WA

<sup>3</sup> Northeastern University, Boston, MA

<sup>4</sup> Enveda Biosciences, Bonn, Germany

<sup>5</sup> Altdeep, Boston, MA

† Corresponding author: ovitek@neu.edu

be likely to die even if they did receive treatment, and who would likely survive only if they received treatment.

## 2 BACKGROUND

**Biological signaling pathways** Signaling pathways are composed of entities that engage in activities [21]. Examples of entities are proteins and metabolites, but also higher level biological processes such as an immune response. Activities are the producers of change. Examples include catalytic activity, kinase activity, or transcriptional activity.

The basic unit of causality in signaling pathways is a directed molecular interaction, where the activity of an upstream molecule increases or decreases the activity of a downstream molecule. For example, the mitogen-activated protein kinase (MAPK) intracellular signaling pathway is a causal chain of directed molecular interactions shown in Eq. (1)

$$a(S_1) \rightarrow \text{kin}(p(\text{Raf})) \rightarrow \text{kin}(p(\text{Mek})) \rightarrow \text{kin}(p(\text{Erk})) \quad (1)$$


The interactions transmit information about a stimulus at the cell surface to the nucleus, where proteins called transcription factors activate an appropriate biological process [22]. A causal diagram of MAPK consists of a signaling molecule  $S_1$  and three proteins  $Raf$ ,  $Mek$ , and  $Erk$ , each of which engage in kinase activity. We represent signaling molecule abundance with  $a()$ , protein abundance with  $p()$  and the kinase activity of a protein with  $\text{kin}()$ . In the case of MAPK, the abundance or activity of an upstream entity causes the abundance or activity of a downstream entity to increase, and is represented with a sharp edge  $\rightarrow$ . The diagram is an abstraction showing that the abundance of the signaling molecule  $S_1$  increases the kinase activity of  $Raf$ , which increases the kinase activity of  $Mek$ , which increases the kinase activity of  $Erk$ . In other cases, if the abundance or activity of an upstream entity causes the abundance or activity of a downstream entity to decrease, we represent this with a blunt edge  $\dashrightarrow$ .

**Viral dysregulation** Viral disruptions of a signaling pathway take form of overactivation or repression of its activities. For example, by amplifying the release of intercellular signaling molecules that overstimulate the immune response, known as Cytokine Release Syndrome (cytokine storm or CytokineStorm), a virus can cause severe system-level cellular damage.

**Quantitative modeling of biological processes with ODE/SDE** Temporal dynamics of biological processes can be expressed quantitatively using ordinary (or stochastic) differential equations. A small number of high quality, validated models have been published in the literature and stored in a computable form in repositories such as Biomodels [23], [24]. For example, the MAPK signaling pathway in Eq. (1) is well characterized. We denote  $R(t)$ ,  $M(t)$ , and  $E(t)$  as the respective amounts of active  $Raf$ ,  $Mek$ , and  $Erk$  at time  $t$ ; We denote  $T_R$ ,  $T_M$ , and  $T_E$  as their total amounts, which we assume do not change during the considered timeframe;  $v_R^{\text{act}}$ ,  $v_R^{\text{inh}}$ ,  $v_M^{\text{act}}$ ,  $v_M^{\text{inh}}$ ,  $v_E^{\text{act}}$ , and  $v_E^{\text{inh}}$  are experimentally derived activation or inhibition kinetic rate constants; and  $S_1$  is the amount of the input signal. The system of ordinary differential equations (ODEs) is specified as follows [25], [26]:

$$\begin{aligned} \frac{dR}{dt} &= v_R^{\text{act}} S_1 (T_R - R(t)) - v_R^{\text{inh}} R(t) \\ \frac{dM}{dt} &= \frac{(v_M^{\text{act}})^2}{v_M^{\text{inh}}} R(t)^2 (T_M - M(t)) - v_M^{\text{act}} R(t) M(t) - v_M^{\text{inh}} M(t) \\ \frac{dE}{dt} &= \frac{(v_E^{\text{act}})^2}{v_E^{\text{inh}}} M(t)^2 (T_E - E(t)) - v_E^{\text{act}} M(t) E(t) - v_E^{\text{inh}} E(t) \end{aligned} \quad (2)$$

Given initial conditions, forward simulations from the ODEs can be used to generate the temporal trajectories of the amounts of activated proteins, such as  $R(t)$ ,  $M(t)$ , and  $E(t)$  in the MAPK example. In this manuscript we refer to such simulated data as *observational data*. We define an *ideal intervention* as an event that fixes the amount of an activated protein. For example, if we fix the kinase activity of  $Mek$  at  $M(t) = m$ , the second equality  $\frac{dM}{dt}$  in Eq. (2) becomes zero. We



**Fig. 1: Causal modeling of MAPK signaling pathway** Circles are variables, double circles are variables intervened upon, squares are deterministic functional assignments, gray nodes are observed variables, and white nodes are hidden variables. (a) Structural causal model.  $N_{Raf}$ ,  $N_{Mek}$  and  $N_{Erk}$  are statistically independent noise variables. Root node  $Raf$  is only dependent on noise variable  $N_{Raf}$ . Non-root nodes  $Mek$  and  $Erk$  are dependent on their parent and on the associated noise variable. (b) Counterfactual model. The intervention fixes the count of phosphorylated  $Mek$  to  $m'$ , such that  $Mek$  is no longer dependent on  $Raf$  and  $N_{Mek}$ . Given an observed data point, counterfactual inference infers the noise variables  $\hat{N}_{Raf}$ , and  $\hat{N}_{Erk}$ .

can simulate data from Eq. (2) with  $\frac{dM}{dt} = 0$ , and refer to these as *interventional data*. Contrasting observational and interventional data helps evaluate the outcome of the intervention [27].

The deterministic ODE ignore the fact that at low concentration, stochasticity becomes a significant factor in determining the reaction [28]. As the collisions between molecules participating in biochemical process become stochastic, a stochastic model is required. In contrast to ODE, a stochastic differential equation model or stochastic differential equation (SDE) specifies biological process as a random process. For example, in the case of MAPK, the random process of the reaction  $Mek \rightarrow Erk$  is specified with

$$\frac{dP_E(t)}{dt} = g_E(t, v_E^{\text{act}}, v_E^{\text{inh}}, M(t)), E(0) = e_0 \quad (3)$$

where  $P_E(t)$  is marginal probability density of  $E(t)$ , function  $g_E$  determines the probability of a state change between  $E(t)$  and  $E(s)$ ,  $s > t$ ,  $e_0$  is initial condition, and  $M(t)$  is the value of its parent  $Mek$  at  $t$ . Once stochastic differential equation are fully specified, one can use, e.g. Gillespie's stochastic simulation algorithm [29] to simulate observational and interventional data, and evaluate the outcomes of interventions.

Unfortunately, even simple ODEs such as the one in the MAPK example are difficult to build *de novo*. This is nearly impossible for novel and poorly studied systems that lack the existence or findability of experimental information describing the structure or boundaries of the process, kinetic equations governing their dynamics [30], rate constants for these equations, or rules governing each agents' states and functions.

**Equilibrium enzyme kinetics** Simpler and more general quantitative models can be specified when a reaction reaches the state of chemical equilibrium [31]. One commonly used such model is *Hill function* in the form of

$$X = \beta \frac{\mathbf{PA}_X^n}{K^n + \mathbf{PA}_X^n} \quad (4)$$

where  $X$  is the abundance of a protein in a causal diagram (such as  $Erk$  in Eq. (1)),  $\mathbf{PA}_X$  is the set of its parents,  $n$  is a parameter interpreted as the number of ligand binding sites of the protein, and  $\beta$  is the total number of molecules of the protein. A special and frequently used case of the Hill function, called *Michaelis-Menten* function, occurs when  $n = 1$ . Although simple to use, these models are deterministic, and do not describe the stochasticity that is a distinctive property of biological systems at low concentrations.

**Modeling biological processes with structural causal models** The stochastic nature of biological processes at steady-state can be

represented by an SCM such as in Fig. (1) (a) [27], [32]. SCMs represent the dependencies between a child node  $X$  and its parents  $\mathbf{PA}_X$  in terms of a deterministic function  $X = f_X(\mathbf{PA}_X, N_X)$  called *structural assignment*, and a noise variable  $N_X$ . In Fig. (1) (a),  $f_{Mek}$  and  $f_{Erk}$  are linear or non-linear structural assignments, and  $N_{Raf}$ ,  $N_{Mek}$ , and  $N_{Erk}$  are statistically independent noise variables with defined probability distributions

$$\begin{aligned} Raf &= N_{Raf}; Mek = f_{Mek}(Raf; N_{Mek}) \\ Erk &= f_{Erk}(Mek, N_{Erk}) \end{aligned} \quad (5)$$

An ideal intervention in an SCM is performed on a functional assignment. For example, an ideal intervention on  $Mek$  sets  $Mek = m'$ , defining a new SCM

$$Raf = N_{Raf}; Mek = m'; Erk = f_{Erk}(Mek, N_{Erk}) \quad (6)$$

An ideal intervention can also be thought of as a process of mutilating the causal graph. For example, intervening on  $Mek$  eliminates its dependence upon  $Raf$ , and therefore the edge from  $Raf$  to  $Mek$  is removed as shown in Fig. (1)(b).

**Counterfactual inference with SCM** Beyond direct model-based predictions, SCMs enable *counterfactual inference*, i.e., the process of inferring the unseen outcomes of a hypothetical intervention given data observed in absence of the intervention [5]. In the context of SCM, counterfactuals are defined as operations

$$Y_{do(T=t')}(u) \triangleq Y_{M_{do(T=t')}}(u) \quad (7)$$

In other words, the outcome  $Y$  that individual  $u$  would have had she received treatment  $t'$  is defined as the value that  $Y$  would have in a structural causal model  $M$  mutilated to replace  $T = f_T(\cdot)$  with  $T = t'$ .

For example, in the MAPK signaling pathway, we may be interested in the counterfactual question: *Having observed the kinase activities of  $Raf = r$ ,  $Mek = m$ ,  $Erk = e$ , what would be the kinase activity of  $Erk$  in a hypothetical experiment where the kinase activity of  $Mek$  was fixed to  $m'$ ?* This counterfactual query is more formally translated into

$$P(Erk_{do(Mek=m')} | Raf = r, Mek = m, Erk = e) \quad (8)$$

The probability distribution in Eq. (8) is estimated with the following steps:

- 1) **Abduction:** Given observational data, estimate the posterior distribution of the noise variables. In the MAPK example, we estimate the posterior distribution of the noise variables:

$$\begin{aligned} \hat{N}_{Raf} &= \{N_{Raf} | Raf = r, Mek = m, Erk = r\} \\ \hat{N}_{Erk} &= \{N_{Erk} | Raf = r, Mek = m, Erk = r\} \end{aligned}$$

Several inference algorithms are available for this task, e.g. Markov Chain Monte Carlo [33], Gibbs sampling [34], or no-u-turn Hamiltonian Monte Carlo (HMC) [35]. In recent years, gradient-based inference algorithms such as stochastic variational inference [36] have become popular, because they can scale to larger models by converting an inference problem into an optimization problem.

- 2) **Intervention:** Apply the intervention to the SCM to generate a mutilated SCM as in Fig. (1)(b). In the MAPK SCM,  $Mek = f_{Mek}(Raf, N_{Mek})$  is replaced with  $Mek = m'$  as shown in Fig. (1)(b).
- 3) **Prediction:** Generate samples from the mutilated SCM using the estimated posterior distribution over the exogenous variables  $\hat{N}_{Raf}$  and  $\hat{N}_{Erk}$  to obtain the counterfactual distribution, as shown in Fig. (1)(b).

**Causal effects** We distinguish between two causal effects. The first is the average treatment effect (ATE or ATE), defined as the difference between the outcome of a hypothetical intervention and the observed

outcome in the entire population. In the MAPK example, the ATE of  $Erk$  upon an intervention fixing  $Raf = r'$  is:

$$\{Erk_{do(Raf=r')} - Erk\} \quad (9)$$

This requires no observational data, and therefore the average treatment effect (ATE or ATE) can be inferred with forward simulation.

On the other hand, the individual treatment effect (ITE or ITE) is defined as the difference between the outcome of a hypothetical intervention and the observed outcome for a specific individual or context. In the MAPK example, the individual treatment effect of  $Erk$  upon an intervention fixing  $Raf = r'$  in a context where  $Raf = r$ ,  $Mek = m$ ,  $Erk = e$  is:

$$\{Erk_{do(Raf=r')} - Erk\} | Raf = r, Mek = m, Erk = e \quad (10)$$

The ITE shares stochastic components of the noise variables between observational and interventional data, and is therefore often more precise than a comparison based on a direct simulation [27].

In cases where domain knowledge is available to describe the systems dynamics in the form of an SDE, the system at equilibrium can be translated into an SCM to enable counterfactual reasoning and estimation of the individual treatment effect [27], [37]. Unfortunately, this process is challenging in novel and poorly studied systems, due to our limited ability to establish the structure of the causal graph.

**Structured knowledge graphs** Although there exist a multitude of biological knowledge bases that are manually curated from the literature [12], [13], [14], [15], [16], the systems biology community has coalesced around a small number of structured knowledge representations that differ mainly in their intended purpose. For example, the Biological Pathway Exchange Language (BioPAX) [17] was designed for pathway database integration [17], and the Systems Biology Graphical Notation (SBGN) [19] was designed for graphical layout [19].

In contrast, the Biological Expression Language (BEL) [20] was specifically designed for manual extraction and automated integration of author statements about causal relationships among biological entities, biological processes, and cellular-level observable phenomena [11]. The syntax of a BEL statement is comprised of a triple in the form of  $\{subject, predicate, object\}$ . Each subject and object represents an activity or abundance whose entities are grounded using terms from standard namespaces. If the subject directly increases the abundance or the activity of the object, we represent this with  $=>$ , and for directly decreasing relationships, we use  $=|$ . BEL statements can be chained together from the object of the first statement to the subject of the next statement, as shown in Fig. (2) for the case of the MAPK pathway.

BEL provides a number of valuable features for causal modeling. First, the restriction of BEL edges to causal relations implies the topology of the BEL graph can be reflected in the topology of the causal model. Second, the language is expressive enough for humans to manually curate a wide range of biological concepts, but formal enough to serve as a training corpus for natural language processing of biomedical literature (BioNLP) competitions [38]. Third, the BEL ecosystem is sufficiently mature that causal knowledge represented in other languages can be readily converted to BEL [39], [40].

## 3 METHODS

### 3.1 Notation, definitions and assumptions

Let  $\mathbf{X} = \{X_i\}$  be a set of variables, such as molecular activities in a signaling pathway. Let  $\mathbf{P} = \{P_j\}$  be a set of causal predicates that link these variables, such as increases, or regulates. Using this notation, we define a knowledge graph  $\mathbb{K}$  as a set of  $k$  triples

$$\mathbb{K} = \{X_i, P_j, X_{i'} | X_i \in \mathbf{X}, P_j \in \mathbf{P}, X_{i'} \in \{\mathbf{X} \setminus X_i\}\}_{j=1}^k \quad (11)$$

We define a causal query  $\mathbb{Q}$  as a set  $\{\mathbf{X}^c, \mathbf{X}^e, \mathbf{X}^z\}$  of variables that are potential causes, effects and covariates of interest for the biological investigation, where

$$\mathbf{X}^c \subset \mathbf{X}, \mathbf{X}^e \subset \mathbf{X} \setminus \mathbf{X}^c, \text{ and } \mathbf{X}^z \subset \mathbf{X} \setminus \mathbf{X}^c \setminus \mathbf{X}^e$$

$$\begin{aligned} \text{kin}(p(\text{fplx:RAF})) &\Rightarrow \text{kin}(p(\text{fplx:MEK})) \\ \text{kin}(p(\text{fplx:MEK})) &\Rightarrow \text{kin}(p(\text{fplx:ERK})) \end{aligned}$$

Fig. 2: **Example BEL statement** The statement details the processes in the MAPK signaling pathway in Eq. (1). The first line states that the kinase activity of RAF directly increases the kinase activity of MEK. The second line states that kinase activity of MEK directly increases the kinase activity of ERK.

**Algorithm 1** *Causal query to Biological Expression Language (QUERY2BEL or <https://github.com/bel2scm>) algorithm*

**Inputs:** knowledge graph  $\mathbb{K}$   
causal query  $\mathbb{Q} = \{\mathbf{X}^c, \mathbf{X}^e, \mathbf{X}^z\}$   
**Outputs:**  $\mathbb{B}$

---

```

1: procedure QUERY2BEL( $\mathbf{X}^c, \mathbf{X}^e, \mathbf{X}^z, \mathbb{K}$ )
2:   ▶ Get all pathways from cause to effect
3:   for each cause  $X_i^c \in \mathbf{X}^c$  and for each effect  $X_j^e \in \mathbf{X}^e$  do
4:     find all pathways  $\{\mathbb{P}(X_i^c, X_j^e)\}$ 
5:   ▶ Get all pathways from covariates to causes
6:   for each covariate  $X_i^z \in \mathbf{X}^z$  and for each cause  $X_j^c \in \mathbf{X}^c$  do
7:     find all pathways  $\{\mathbb{P}(X_i^z, X_j^c)\}$ 
8:   ▶ Get all pathways from covariates to effects
9:   for each covariate  $X_i^z \in \mathbf{X}^z$  and for each effect  $X_j^e \in \mathbf{X}^e$  do
10:    find all pathways  $\{\mathbb{P}(X_i^z, X_j^e)\}$ 
11:    $\mathbb{B} = \{\mathbb{P}(X_i^c, X_j^e)\} \cup \{\mathbb{P}(X_i^z, X_j^c)\} \cup \{\mathbb{P}(X_i^z, X_j^e)\}$ 
12:   return  $\mathbb{B}$ 

```

---

A pathway  $\mathbb{P}(X_1, X_{k'+1})$ ,  $k \leq k'$  is a sequence of a subset of triples from  $\mathbb{K}$ , where the object of the previous triple is subject of the next triple

$$\{(X_1, P_1, X_2), (X_2, P_2, X_3), \dots, (X_{k'}, P_{k'}, X_{k'+1})\} \quad (12)$$

Our goal is to query the knowledge graph to generate a qualitative causal model  $\mathbb{B}$  that links the causes, the effects and the covariates of interest. Importantly, the query result  $\mathbb{B}$  induces a directed acyclic graph  $G$  with  $p$  variables from  $\mathbf{X}$  as nodes, and causal relations from  $\mathbf{P}$  as edges.

We assume that every variable in  $\mathbb{B}$  is continuous. We denote  $\mathbb{D} = \{X_{1j}, X_{2j}, \dots, X_{pj}\}_{j=1}^m$  the observational data of  $m$  samples from the joint distribution  $\mathcal{P}(\mathbf{X}; \theta)$ . The distribution is specified in terms of parameters  $\theta$ . We denote  $\mathbf{R} \subset \mathbf{X}$  a set of nodes in  $G$  without parents.

### 3.2 Querying a knowledge graph to obtain a qualitative causal model

Given a biological knowledge graph  $\mathbb{K}$  and a causal query of interest  $\mathbb{Q}$ , our first objective is to generate a qualitative causal model  $\mathbb{B}$  capable of answering the query. To this end, we need to explore all potential directed acyclic paths in  $\mathbb{K}$  from the cause to the effect in  $\mathbb{Q}$ , and then consider all covariates that may act as confounders of the causal question. This is done with the steps in Alg. 1. The algorithm can be implemented on any knowledge graph that represents causal relationships as directed edges, such as BEL or the Systems Biology Graphical Notation Activity Flow [19] (SBGN-AF) language [41].

In the case of MAPK, the qualitative causal model that is capable of answering the counterfactual question in Eq. (8) corresponds to the result of this query:  $\mathbb{Q} = \{\mathbf{X}^c = \text{kin}(p(\text{MEK})), \mathbf{X}^e = \text{kin}(p(\text{ERK})), \mathbf{X}^z = \text{kin}(p(\text{RAF}))\}$ .

We execute Alg. 1 step 2 to obtain all pathways from the cause to the effect:

$$\text{kin}(p(\text{MEK})) \rightarrow \text{kin}(p(\text{ERK}))$$

We execute Alg. 1 step 5 to obtain all pathways from the covariate to the cause:

$$\text{kin}(p(\text{RAF})) \rightarrow \text{kin}(p(\text{MEK}))$$

**Algorithm 2** *Biological Expression Language to Structural Causal Models (BEL2SCM or <https://github.com/bel2scm>) algorithm*

**Inputs:** BEL statements  $\mathbb{B}$   
 $\mathbb{D} \sim P(X_1, \dots, X_p)$   
**Outputs:** SCM  $\mathbb{M} = \{f_i(\mathbf{PA}_i, N_i)\}_{i=1}^p$

---

```

1: procedure BEL2SCM( $\mathbb{B}, \mathbb{D}$ )
2:    $\mathbb{M} = \{\}$ 
3:   Get network structure  $G$  from  $\mathbb{B}$ .
4:   for each  $R \in \mathbf{R}$  in  $G$  do
5:     ▶ Use  $\mathbb{D}$  to estimate parameters  $\theta$  of  $\mathcal{P}(R; \theta)$ 
6:      $\theta = \arg \max_{\theta} \mathcal{P}(R; \theta | \mathbb{D})$ 
7:     ▶ Reparameterize  $\mathcal{P}(R; \theta)$  in terms of  $f_R$  and  $N_R$ 
8:      $N_R \sim \mathcal{N}(0, 1)$ 
9:      $f_R(N_R) = F_{\mathcal{P}(R; \theta)}^{-1}(N_R)$ 
10:     $\mathbb{M}.\text{Add}(f_R(N_R))$ 
11:   for each  $X \in \{\mathbf{X} \setminus \mathbf{R}\}$  in  $G$  do
12:     ▶ Estimate parameters  $\mathbf{w}$  and  $b$  of sigmoid function
13:      $\log(\frac{X}{\beta_X - X}) = \mathbf{w}'\mathbf{PA}_X + b$ 
14:     ▶ Define distribution of  $N_X$  from model residuals.
15:      $\text{residual} = X - \frac{\beta_X}{1 + \exp(-\mathbf{w}'\mathbf{PA}_X - b)}$ 
16:      $N_X \sim \mathcal{N}(0, \text{MSE}(\text{residual}))$ 
17:     ▶ Get  $f_X(\mathbf{PA}_X, N_X)$  with additive  $N_X$ .
18:      $f_X(\mathbf{PA}_X, N_X) = \frac{\beta_X}{1 + \exp(-\mathbf{w}'\mathbf{PA}_X - b_X)} + N_X$ 
19:      $\mathbb{M}.\text{Add}(f_X(\mathbf{PA}_X, N_X))$ .
20:   return  $\mathbb{M}$ 

```

---

We execute Alg. 1 step 8, but since there are no new pathways from the covariate  $\text{kin}(p(\text{RAF}))$  to the effect  $\text{kin}(p(\text{ERK}))$ , we obtain the empty set. The final returned model is:

$$\text{kin}(p(\text{RAF})) \rightarrow \text{kin}(p(\text{MEK})) \rightarrow \text{kin}(p(\text{ERK}))$$

### 3.3 Compiling a qualitative causal model to a quantitative structural causal model

Our second objective is to express the qualitative causal structure in  $\mathbb{B}$  into a quantitative SCM, and estimate the parameters of the SCM from experimental data. These steps are described in Algorithm 2.

**Input** The algorithm takes as input a BEL causal query result  $\mathbb{B}$  and observed measurements on its variables  $\mathbb{D}$ .

**Get network structure  $G$  from  $\mathbb{B}$  (Alg. 2 line 3)** Since a set of BEL statements identifies parents and children, it induces a causal network structure. We determine this structure by traversing BEL statements with the breadth first search approach, starting with root variables (such as *Raf* in Figure 2). For all the non-root variables, the algorithm waits until all the parents are traversed.

**For each root node  $R$ , use  $\mathbb{D}$  to estimate parameters  $\theta$  of  $\mathcal{P}(R; \theta)$  (Alg. 2 line 5)** In order to specify the SCM, we need to define the type and parameters of the marginal probability distributions of the root variables  $\mathcal{P}(R; \theta)$ . The BEL statements provide prior knowledge about the distribution in a parametric form. Therefore, this step involves techniques such as maximum likelihood to estimate the parameters of this distribution.

For example, in a stochastic MAPK system at equilibrium the root variable the number of active *Raf* in a cell follows a Binomial distribution. When the maximum number of active or inactive particles in the system is large, the Binomial distribution can be approximated




Fig. 3: **Examples of Hill function and sigmoid function for two variables**  $X$  is a single node that has a single parent  $\mathbf{PA}_X$ . We use the Hill function ( $X = \beta \frac{\mathbf{PA}_X^n}{K^n + \mathbf{PA}_X^n}$ ) and sigmoid function as in Eq. (15) to predict the value of  $X$  given its parent value. In the Hill function,  $K$  is the activation rate,  $n$  defines the steepness of function and  $\beta$  is fixed at 100. Blue lines correspond to Hill equation with  $K = 30$  and  $n \in \{1, 2, 3\}$ . Brown lines correspond to sigmoid function where  $b \in \{0.4, 0.3, 0.4\}$  and  $w \in \{0.025, 0.1, 0.5\}$

with a Normal distribution with  $\theta_{Raf} = (\mu_{Raf}, \sigma_{Raf}^2)$ . We then estimate  $\theta_{Raf}$  using maximum likelihood from the observed  $Raf$  in  $\mathbb{D}$ .

**For each root node  $R$ , reparameterize  $\mathcal{P}(R; \theta)$  in terms of  $f_R$  and  $N_R$  (Alg. 2 line 7)** The specification of an SCM requires us to separate the deterministic and the stochastic components of variation of each variable as shown in Fig. (1). We accomplish this using a reparameterization technique popularized by variational autoencoders [42], which was shown to make counterfactual inference consistent with core biological assumptions [43]. In the case of root nodes, we reparameterize  $\mathcal{P}(R; \theta)$  with Uniform(0,1), and then pass it to the inverse CDF of  $\mathcal{P}(R; \theta)$ , as follows

$$\begin{aligned} \text{Original :} & \quad R \sim \mathcal{P}(R; \theta) \\ \text{Reparameterized :} & \quad N_R \sim \text{Uniform}(0, 1) \\ & \quad f_R(N_R) = F_{\mathcal{P}(R; \theta)}^{-1}(N_R) \end{aligned} \quad (13)$$

where  $F_{\mathcal{P}(R; \theta)}^{-1}(N_R)$  is the inverse cumulative distribution function of  $\mathcal{P}(R; \theta)$ . In the case of MAPK, since  $Raf$  follows a Normal distribution with parameters  $\theta_{Raf}$ , the reparameterization simplifies even further to

$$\begin{aligned} \text{Original :} & \quad Raf \sim \mathcal{N}(\mu_{Raf}, \sigma_{Raf}^2) \\ \text{Reparameterized :} & \quad N_{Raf} \sim \mathcal{N}(0, 1) \\ & \quad f_{Raf}(N_{Raf}) = \sigma_{Raf} N_{Raf} + \mu_{Raf} \end{aligned} \quad (14)$$

**Add  $R$  to  $\mathbb{M}$  (Alg. 2 line 10)** For each root node, we add the corresponding function  $f_R(N_R)$  and its noise variable  $N_R$  to  $\mathbb{M}$ . For example, since MAPK has only one root node  $Raf$ , the Algorithm adds  $f_{Raf}(N_{Raf})$  to  $\mathbb{M}$ .

**For each  $X \in \{\mathbf{X} \setminus \mathbf{R}\}$ , estimate parameters  $\mathbf{w}$  and  $b$  of sigmoid function (Alg. 2 line 12)** In order to specify the SCM for non-root nodes, we need to define the form (polynomial, linear, non-linear, sigmoid, etc.) of functional assignments linking the measurements on the parent nodes to the measurements on the child. We chose the functional assignment in the form of a sigmoid function

$$\log\left(\frac{X}{\beta_X - X}\right) = \mathbf{w}'\mathbf{PA}_X + b \quad (15)$$

where  $\beta_X$  is the maximum number of activated protein molecules. For a node  $X$  with  $q$  parents,  $\mathbf{PA}_X$  is a  $q \times 1$  vector of measurements on

the parent nodes,  $\mathbf{w}$  is a  $1 \times q$  vector of weights,  $\mathbf{w}'$  is the transpose of  $\mathbf{w}$ , and  $b$  is a scalar bias. Parameters  $\mathbf{w}$  and  $b$  of the sigmoid function are estimated from the data, e.g. using smooth  $L_1$  loss function.

In the example of the MAPK pathway,  $f_{Mek}$  has only one parent. Therefore  $f_{Mek}$  has the form

$$f_{Mek}(Raf, N_{Mek}) = \frac{\beta_{Mek}}{1 + \exp(-w_{Mek}Raf - b)} + N_{Mek} \quad (16)$$

We use the sigmoid function in Eq. (15) as a special case of the Hill equation. The full parametric description of the Hill equation has a nuanced precise biochemical interpretation. For example, the parameter  $n$  represents the number of times a protein must be phosphorylated before it becomes active and can therefore be obtained from domain knowledge. However, it is difficult to estimate this parameter from data. The sigmoid function maintains the Hill equation's functions, but with a reduced set of parameters that are easier to estimate. Fig. (3) shows that the approximation is reasonable for a range of parameter values.

**Define distribution of  $N_X$  from model residuals (Alg. 2 line 14)** Similarly to the root variables, for non-root variables we assume that the noise variables follow Normal distribution with 0 mean. The variance of this distribution is estimated from the residuals of the model fit in the previous step. For example, in the MAPK pathway,  $f_{Mek}$  has only one parent  $Raf$ . Therefore, the residuals of the sigmoid curve fit for  $Mek$  are defined as

$$residual_{Mek} = Mek - \frac{\beta_{Mek}}{1 + \exp(-w_{Mek}Raf - b)} \quad (17)$$

and the distribution of the noise variable is defined as  $N_{Mek} \sim \mathcal{N}(0, MSE(residual_{Mek}))$

**Get  $f_X(\mathbf{PA}_X, N_X)$  with additive  $N_X$  (Alg. 2 line 17)** The step combines the sigmoid functional assignment and the independent noise variable. In the example of  $Mek$  in the MAPK pathway, the step outputs

$$f_{Mek}(Raf, N_{Mek}) = \frac{\beta_{Mek}}{1 + \exp(-w_{Mek}Raf - b)} + N_{Mek} \quad (18)$$

**Add  $f_X(\mathbf{PA}_X, N_X)$  to SCM (Alg. 2 line 19)** The step iteratively adds  $(f_X, N_X)$  for all  $X \in \mathbf{X}$ .

**Output (Alg. 2 line 20)** The algorithm returns a generative structural causal model  $\mathbb{M} = \{f_i(\mathbf{PA}_i, N_i)\}_{i=1}^p$  where  $\mathbf{PA}_i \subset \mathbf{X}$ . For example, in the case of the MAPK model, it returns  $[N_{Raf}, N_{Mek}, N_{Erk}, f_{Raf}(N_{Raf}), f_{Mek}(Raf, N_{Mek}), f_{Erk}(Mek, N_{Erk})]$ .

### 3.4 Counterfactual inference procedure

The generated SCM enables counterfactual inference using a standard procedure [5]. Given a new observation  $\mathbb{D}^{new}$ ,

- 1) **Abduction:** Update the probability  $P(N_X)$  to obtain  $P(N_X | \mathbb{D}^{new})$ .
- 2) **Action:** Replace the equations determining the variables in set  $\mathbf{X}^c$  by  $\mathbf{X}^c = \mathbf{x}^{c'}$ .
- 3) **Prediction:** Sample from the modified model to generate the target distribution  $\mathbf{X}_{do(\mathbf{X}^c = \mathbf{x}^{c'})}^c$ .

After generating the target distribution of the intervention model, we estimate causal effects. Alg. 3 describes the detailed steps of both counterfactual inference (with  $\mathbb{D}^{new}$ ) and forward simulation (if  $\mathbb{D}^{new}$  is empty)

### 3.5 Implementation

Causal query to Biological Expression Language (QUERY2BEL or <https://github.com/bel2scm>) was implemented manually using a publicly available instance of BioDati Studio [44], then validated using Integrated Dynamical Reasoner and Assembler (INDRA) [10]'s interactive dialogue system Bob with BioAgents [10]. Parameter estimation in Biological Expression Language to Structural Causal

**Algorithm 3** Estimate causal effect on  $X^E$  upon intervening on  $X^C$ 

**Inputs:** New data point  $\mathbb{D}^{new}$   
 effect node  $X^E$   
 observational data for effect node  $\mathbb{D}^E \in \mathbb{D}^{new}$   
 intervention value  $c$   
 node to intervene upon  $X^C$   
 number of iteration  $I$   
 network structure  $G$   
 SCM  $\mathbb{M}$

**Outputs:** Causal Effect  $CE$

```

1: procedure GETCAUSALEFFECT( $\mathbb{D}^{new}, E, \mathbb{D}^E, X^C, c, I, G, \mathbb{M}$ )
2:    $\hat{N} = \{\}$ 
3:   ► Interventional data for effect node  $X^E$ 
4:    $\mathbb{I}\mathbb{D}^E = \{\}$ 
5:   for  $I$  do
6:     for each  $X \in \{X \setminus X^C\}$  in  $G$  do
7:       ► Abduction: Apply stochastic variational inference
8:        $\hat{N}_X = SVI(\mathbb{D}^{new})$ 
9:        $\hat{N}.Add(\hat{N}_X)$ 
10:      ► Action: Apply intervention on  $X^C$ 
11:       $CM = pyro.do(\mathbb{M}, X^C = c)$ 
12:      ► Get posterior of  $CM$  with importance sampling
13:       $CMP = pyro.infer.Importance(CM, \hat{N})$ 
14:      ► Prediction: Get EmpiricalMarginal (EM) for  $X^E$ 
15:       $CMM = pyro.infer.EM(CMP, X^E)$ 
16:       $\mathbb{I}\mathbb{D}^E.Add(CMM)$ 
17:    $CE = \mathbb{I}\mathbb{D}^E - \mathbb{D}^E$ 
18:   return  $CE$ 

```

Models (BEL2SCM or <https://github.com/bel2scm>) was implemented in PyTorch. Let  $C$  be the number of nodes in causal graph  $G$  with parents. Let  $k$  be the number of iterations for gradient descent, let  $N$  be the number of samples in data, and let  $d$  be the maximum number of parents in graph  $G$ . Computational complexity of parameter estimation step is given by  $O(CkNd)$ .

SCM-based counterfactual inference was performed with Pyro [45], due to its ability to perform interventions on probabilistic models and scalability to larger models, as described in Alg. 3. Specifically, the implementation relies on the following functionalities in Pyro. The `pyro.do` method is an implementation of Pearl’s do-operator used for causal inference. The `pyro.infer.SVI` method performs abduction using stochastic variational inference with ELBO loss. The `pyro.infer.Importance` method performs posterior inference by importance sampling. The `pyro.infer.EmpiricalMarginal` method performs empirical marginal distribution from the trace posterior’s model.


Experiments in this manuscript took between 13 to 82 seconds depending on the graph size on a system with Intel Core i7 8th Gen CPU, 16 GB RAM and Ubuntu 18.04 Operating System. The code is available at <https://github.com/bel2scm>.

## 4 CASE STUDIES

Below we introduce two biological case studies investigated using the approach proposed in this manuscript. The first case study allows us to evaluate the accuracy of the results based on known ground truth. The second uses counterfactual reasoning to pinpoint the mechanism by which SARS-CoV-2 infection can lead to a cytokine storm in severely ill coronavirus disease 2019 (COVID-19) patients. The details of the case studies, parameter values of the simulations, and of the results are at <https://github.com/bel2scm>.

### 4.1 Case study 1: the IGF signaling system

**The system** The insulin-like growth factor (IGF) signaling pathway (Figure 4) regulates growth and energy metabolism of a cell. The IGF system has been extensively investigated, and its dynamics are well characterized in form of ODE and SDE models [25]. Activated by



**Fig. 4: Case Study 1: the IGF signaling system** The insulin-like growth factor (IGF) and epidermal growth factor (EGF) are receptors of external stimuli, triggering downstream signaling pathways that include the MAPK pathway. All the relationships between abundances of activated proteins in this network are of the type *increase*, except for the relationship between *Akt* and *Raf* which is of the type *decrease*.

external stimuli, insulin-like growth factor (IGF) or epidermal growth factor (EGF) triggers a signaling event, which includes the MAPK signaling pathway in Eq. (1). Similarly to Eq. (1), nodes in the system are kinase activities, and edges represent whether the kinase activity of the upstream protein directly increases or decreases the kinase activity of the downstream protein. However, the system is larger and more complex. It includes two different paths from *Ras* to *Erk*, one direct and the other through *PI3K* and *Akt*. This challenges estimates of outcomes of interventions. In this case study, we assume that the IGF system has no unobserved confounders.

**Intervention** We considered two interventions. The first fixes the kinase activity of *Mek* to 40. The second fixes the kinase activity of *Ras* to 30.

**Causal effects of interest** We are interested in two causal questions. First, *what would have been the kinase activity of Erk had we intervened to fix the kinase activity of Mek to 40?* The second query is as above, but with the intervention fixing the kinase activity of *Ras* to 30. More formally, we are interested in the average treatment effect

$$\{Erk_{do(Mek=40)} - Erk\} \quad (19)$$

$$\{Erk_{do(Ras=30)} - Erk\} \quad (20)$$

Next, we introduce a new piece of information about a specific data point generated from the ODE-based simulation. We wish to estimate the causal effect of intervention for this specific data point. More formally, we are interested in the individual treatment effect

$$\{Erk_{do(Mek=40)} - Erk\} | \mathbb{D}^{new} \quad (21)$$

$$\{Erk_{do(Ras=30)} - Erk\} | \mathbb{D}^{new} \quad (22)$$

where  $\mathbb{D}^{new}$  is a new data point. We note that this counterfactual inference can only be performed with an SCM. We wish to compare these estimates of causal effects, in order to characterize the ability of counterfactual inference via  $\mathbb{D}^{new}$  to improve the precision of the estimates.

**Evaluation** The kinetic equations described by the ODE and SDE represent the true underlying dynamics of the IGF signaling pathway. Since the ODE and the SDE can estimate the causal effects by forward simulation, we view the estimates as the ground truth. We then wish to compare the estimates from the SCM against the ground-truth estimates from the ODE and the SDE. Since an SCM represents causal

relationships at steady state, we train the parameters of the SCM using data generated from the ground-truth SDE after it has reached steady state.

We consider two types of evaluations. First, we compare the estimates of the forward simulation of the ODE and SDE with the forward simulation of the SCM. This allows us to characterize the impact of SCM specification and estimates of weights on the accuracy of causal effects. We do not expect to see a substantial difference between these two approaches for a correctly specified SCM. We then compare the SCM-based counterfactual inference of causal effects with the estimates based on forward simulation. We expect that the counterfactual inference will provide more precise estimates, illustrating the statistical efficiency of counterfactual inference as compared to the forward simulation.

## 4.2 Case study 2: host response to viral infection

**The system** Retrospective studies have indicated that high levels of pro-inflammatory cytokine Interleukin 6 (IL6 or IL6) are strongly associated with severely ill COVID-19 patients [46]. One recently proposed explanation for this is the viral induction of a positive feedback loop, known as Interleukin 6 Amplifier (IL6-AMP or IL6-AMP) [47]. IL6-AMP is stimulated by simultaneous activation of nuclear factor kappa-light-chain-enhancer of activated B cell (NF- $\kappa$ B or NF- $\kappa$ B) and Signal Transducer and Activator of Transcription 3 (STAT3 or STAT3) [48]. This in turn induces various pro-inflammatory cytokines and chemokines, including Interleukin 6, which recruit activated T cells and macrophages. This strengthens the Interleukin 6 Amplifier into a positive feedback loop leading to a cytokine storm [49], which is believed to be responsible for the tissue damage observed in patients with acute respiratory distress syndrome (ARDS) [47].

**Intervention** Originally developed to treat autoimmune disorders such as rheumatoid arthritis [50], Tocilizumab (Toci or Toci) is an immunosuppressive drug consisting of a recombinant monoclonal antibody that targets the soluble Interleukin 6 receptor and can effectively block the IL6 signal transduction pathway [51]. Tocilizumab has emerged as a promising drug repurposing candidate to reduce mortality in severely ill COVID-19 patients [52], [53].

**Causal effect of interest** We define a severely ill COVID-19 patient as someone with CytokineStorm  $> 65$ . We are interested in the individual treatment effect (ITE)

$$\left\{ \text{CytokineStorm}_{do(Toci=0)} - \text{CytokineStorm} \right\} | \mathbb{D}^{new} \quad (23)$$

where  $\mathbb{D}^{new}$  is an observed patient who received Tocilizumab treatment and became severely ill. We wish to characterize the severity of cytokine storm which would have occurred had she not received the treatment. We further wish to compare the ITE with the average treatment effect (ATE or ATE)

$$\left\{ \text{CytokineStorm}_{do(Toci=0)} - \text{CytokineStorm} \right\} \quad (24)$$

**Evaluation** Tocilizumab is known to have a strong inhibitory effect on soluble Interleukin 6 receptor. We therefore expect that the severity of the cytokine storm would have been worse had the patient not received treatment. Unfortunately, at the time of writing, there were no ODE or SDE-based models of the pathway, nor were there publicly available COVID-19 datasets quantifying the kinase activity of the Interleukin 6 Amplifier pathway at the single-cell level. Therefore, we simulated data from a ‘‘ground-truth’’ sigmoidal structural causal model, where the topology reflects the causal structure of the pathway, and the numeric values of the parameters were fixed to reflect our prior qualitative knowledge of the IL6-AMP pathway.

We evaluate the ITE the proposed approach in two ways. First, we train the parameters of the SCM using the simulated data, and compare the counterfactual inference of the ITE obtained from the ‘‘trained’’ SCM to the counterfactual inference of the ITE from the ‘‘ground-truth’’ SCM. This comparison allows us to characterize the impact of weight




Fig. 5: **Case study 1: IGF model** Scatter plot of *Mek* versus *Raf*. Blue points are the data points generated by SDE. Yellow points are the estimates from SCM. The red line is the fitted sigmoid curve in Alg. 2 line 12.




Fig. 6: **Case study 1: probability distributions of the root nodes of IGF model** (a) Histogram of *SOS* generated from SDE simulation (b) As in (a), for *PI3K*.

estimation on the accuracy of causal effects. We expect that the need to estimate the weights will inflate the variance of the estimates. Second, we compare the estimates of ITE to the estimates of the ATE using the trained SCM. This comparison allows us to characterize the statistical efficiency of counterfactual inference when estimating causal effects. We expect that the ITE will provide much more precise estimates.

## 5 RESULTS

### 5.1 Case study 1: the IGF signaling system


**Generating BEL causal model** The BEL representation of the IGF system was manually curated using BioDati studio [44], to match the existing ODE and SDE. The BEL representation of the IGF system specified all the node types as in category *abundance*. All the relationships between parents and children nodes were of type *increase*, except for the parent node *Akt*, where the relationship was of type *decrease*.

**Observational data** We mimicked the process of collecting observational data by simulating kinase activity from the corresponding ODE and SDE. The initial number of particles for the receptor was 37 for *EGF* and 5 for *IGF*. The deterministic simulation numerically solved the ODE using the *deSolve* [54] R package. The stochastic simulation used the Gillespie algorithm [29] from the *smfsb* [55] R package.

**Appropriateness of model assumptions** SCM-based estimates of functional assignments with sigmoid approximations were well within the range of the SDE-based data (as shown for *Raf* and *Mek* in Fig. (5)). Similar results were obtained for estimates of *Ras*, *PI3K*, *AKT*, *Raf*, and *Erk*. The fitted functional assignment had little curvature. This indicates that a more complicated function with more parameters, such as Hill equation, was unnecessary in this case.

To further evaluate the plausibility of the assumptions, Fig. (6) shows the histograms of the SDE-generated abundances of root nodes,





**Fig. 7: Case study 1: estimated causal effects of the IGF signaling pathway using Alg. 3.** The ODE and SDE represent the true underlying dynamics of the IGF signaling pathway. The ODE and SDE-based forward simulation can only estimate the average treatment effect. These estimates are viewed as ground truth. In contrast, an SCM can estimate both the average treatment effect (ATE) and the individual treatment effect (ITE). (a) Comparison of ITE vs ATE for *Erk* when *Mek* is fixed. (b) Comparison of ITE vs ATE for *Erk* when *Ras* is fixed. (c) Comparison of SCM, SDE and ODE estimates of the ATE for *Erk* when *Mek* is fixed. (d) Comparison of SCM, SDE and ODE estimates of the ATE on *Erk* when *Ras* is fixed.


which were not affected by functional assignments in SCM. The shape of the histograms indicate that the assumption of Normal distribution was plausible.

**Accuracy of causal effects** Fig. (7)(c) and (d) show that the average treatment effects (ATEs or ATEs) on *Erk* of fixing *Mek* and *Raf*, based on forward simulation of ODE, SDE and SCM, were consistent. Fig. (7)(a) and (b) show that the individual treatment effects (ITEs or ITEs) based on counterfactual inference has a smaller variance than the ATE. Since counterfactual inference reduces nuisance variation by sharing stochastic components in contexts with and without intervention, it increases the statistical efficiency of the estimation.

The individual treatment effect on *Erk* by fixing *Mek* was much stronger than the ITE on *Erk* by fixing *Ras* for the following reason. While *Mek* directly influences *Erk* (i.e., there is a single path from *Mek* to *Erk*), *Ras* has two pathways to *Erk*. The path through *AKT* has an inhibiting (deactivation) effect on *Raf*, and estimated negative weights in the sigmoid function in Eq. (15). The alternative path, a cascade from *Ras* to *Erk*, has the opposite (activating) effect on *Erk*. The two paths mitigate the overall causal effect of *Ras* on *Erk*.

## 5.2 Case study 2: host response to viral infection

**Generating BEL causal model** The steps of the proposed Alg. 1 produced the qualitative causal model in Fig. (8), and the corresponding BEL causal model  $\mathbb{B}$ , as follows. In accordance with the inputs to Alg. 1, we defined the knowledge base  $\mathbb{K}$  as the Covid-19 knowledge network automatically assembled from the COVID-19 Open Research Dataset (CORD-19) [56] document corpus using the INDRA workflow. We defined the cause  $\mathbf{X}^c$  as *sIL6R $\alpha$* , the



**Fig. 8: Case study 2: host response to viral infection** Pointed edges represent relationships of type *increase*; flat-headed edges represent relationships of type *decrease*. Nodes SARS-COV2 and Toci are external stimuli.

effect  $\mathbf{X}^e$  as cytokine storm, and the covariates  $\mathbf{X}^z$  as SARS-CoV-2 and Toci. Therefore the causal query of interest was defined as  $\mathbb{Q} = \{sIL6R\alpha, CytokineStorm, \{SARS-CoV-2, Toci\}\}$ .

Alg. 1 line 2 generated all pathways from soluble Interleukin 6 receptor to Cytokine Release Syndrome, resulting in  $kin(p(sIL6R\alpha)) \rightarrow kin(p(IL6-STAT3)) \rightarrow bp(IL6-AMP) \rightarrow bp(CytokineStorm)$ , where  $bp()$  is a biological process. Next, line 5 generated all pathways from Tocilizumab to soluble Interleukin 6 receptor:  $a(Toci) \rightarrow kin(p(sIL6R\alpha))$ , where  $a()$  is the dosage level of Tocilizumab. We then generated all pathways from severe acute respiratory syndrome coronavirus 2 to soluble Interleukin 6 receptor:  $pop(SARS-CoV-2) \rightarrow cat(ACE2) \rightarrow a(Angiotensin II) \rightarrow kin(p(AGTR1)) \rightarrow kin(p(ADAM17)) \rightarrow kin(p(sIL6R\alpha))$ , where  $pop()$  is the viral load of SARS-CoV-2 and  $cat()$  is the normal catalytic activity of Angiotensin Converting Enzyme 2.

Line 8 found no new branches from Tocilizumab to Cytokine Release Syndrome. Finally, we generated all pathways from severe acute respiratory syndrome coronavirus 2 to Cytokine Release Syndrome, which resulted in three new branches  $pop(SARS-CoV-2) \rightarrow kin(p(PRR)) \rightarrow kin(p(NF-\kappa B)) \rightarrow bp(IL6-AMP)$ ,  $kin(p(ADAM17)) \rightarrow p(EGF) \rightarrow kin(p(EGFR)) \rightarrow kin(p(NF-\kappa B))$ , and  $kin(p(ADAM17)) \rightarrow kin(p(TNF\alpha)) \rightarrow kin(p(NF-\kappa B))$ .

**Observational data** We simulated observational data from a “ground-truth” sigmoidal structural causal model, where the topology reflects the causal structure in Fig. (8), and the parameters reflect our prior qualitative knowledge of the IL6-AMP pathway. The root nodes SARS-CoV-2 and Tocilizumab were sampled from a Normal distribution with mean of 50 and standard deviation of 10. The non-root nodes were sampled from a sigmoid function as in Eq. (15). Since we have prior qualitative knowledge that IL6-AMP is only activated due to simultaneous activation of NF- $\kappa$ B and IL6-STAT3, we set the threshold for activation above what could be achieved by NF- $\kappa$ B or IL6-STAT3 alone. Since we also know that Toci is a strong inhibitor of *sIL6R $\alpha$* , we set the inhibition coefficient to a large negative number. The parameters of the sigmoid function were chosen to ensure that the variables were in the desired range of 0–100. Finally, we randomly generated two new individuals  $\mathbb{D}^{new}$  with Cytokine Release Syndrome  $> 65$  to represent severely ill patients. The first patient had a higher viral load of SARS-CoV-2 and received a lower dose of Toci. The second patient had a lower viral load of and received a higher dose of Toci.

**Estimation of individual-level treatment effect** Fig. (9) evaluates the SCM-based estimates of the individual treatment effect of withholding




Fig. 9: Case study 2: SCM-based estimates of the individual treatment effect (ITE or ITE) using Alg. 3. Blue histogram: the ITE estimated from the ground-truth SCM using Alg. 3. Yellow histogram: the ITE estimated from the Alg. 2-trained SCM using Alg. 3. (a) Patient has a high viral load and received a low dose of Tocilizumab. (b) Patient has a low viral load and received a high dose of Tocilizumab. Both patients were severely ill.




Fig. 10: Case study 2: SCM-based estimates of the average treatment effect (ATE or ATE) and of the ITE using Alg. 3. Yellow histogram: the ITE estimated using counterfactual inference. Brown histogram: the ATE estimated using forward simulation. (a) Patient has a high viral load and received a low dose of Tocilizumab. (b) Patient has a low viral load and a received a high dose of Tocilizumab. Both patients were severely ill.

treatment from two COVID-19 patients who were severely ill. The distribution of the individual treatment effect obtained with the SCM trained using Alg. 2 was consistent with, but had a slightly larger variance than, the distribution of ITE obtained with the “ground truth” SCM with known weights. Even though both patients had the same severity of illness prior to the intervention, patient B was estimated to have a more severe cytokine storm after Toci was withheld.

Fig. (10) further compared the individual treatment effect obtained with the SCM trained using Alg. 2 with the average treatment effect estimated from the same model using forward simulation. The distribution of the individual treatment effect was patient-specific and had smaller variance, thus illustrating the statistical efficiency of counterfactual inference.

## 6 DISCUSSION

We proposed a general approach that leverages structured qualitative prior knowledge, automatically generates a quantitative SCM, and enables answers to counterfactual research questions. In both case studies, the use of the Biological Expression Language allowed us to leverage large repositories of structured biological knowledge to specify an SCM and perform counterfactual inference in an automated manner, which would otherwise require a substantial manual

effort. The application to the IGF signaling system demonstrated the appropriateness of the underlying assumptions, and the accuracy of the results when compared to ODE- and SDE-based forward simulation. The application to a study of host response to SARS-CoV-2 infection demonstrated the feasibility, versatility and usefulness of this approach as applied to an urgent public health issue. In particular, the approach can help determine the amount of Tocilizumab (Toci or Toci) required to reduce the severity of each individual’s cytokine storm. Furthermore, in situations where treatment options are limited (as is the case SARS-CoV-2), counterfactual estimates enable a more precise conclusion regarding who would likely live without receiving the treatment, who would likely die even if they did receive the treatment, and who would likely live only after receiving the treatment.

The approach opens multiple directions for future research. In particular, future work can extend the configurability of the BEL2SCM algorithm by incorporating the rich type information in BEL, mapping parent-child type signatures to functional forms such as post-nonlinear models, neural networks, mass action kinetics and Hill equations, and incorporating additional data types such as binary variables, categorical variables, and continuous variables with constraints on their domains. In some cases, the variables in the model may not be directly observable, but may nonetheless be characterized by means of detectable molecular signatures. For example, even if interferon signaling may not be directly observable using transcriptomics measurements, it may still be possible to infer the activity of interferon signaling by an upregulation of interferon stimulated genes (ISG). Future work will focus on leveraging molecular signature databases to infer the activity of variables in the model, and on learning and/or evaluating the models using experimental data [57].

We also note that experimentalists typically formulate biological processes as linear pathways (e.g., from  $S_1$  to *Erk* in the MAPK example) that can be effectively perturbed and measured in a laboratory setting. Yet such boundaries of biological processes are quite arbitrary, and are therefore highly susceptible to confounders. One way to address this issue is to search the knowledge graph for all common causes of variables in the causal model, use an identification algorithm [58] to find the minimal valid adjustment set of the augmented model, and then prune all common causes that do not contribute to that set. This approach will require us to tackle the issues of parameter and causal identifiability in the presence of confounders.

In addition to unobserved confounders, the validity of causal inferences can be threatened by feedback loops, model misspecification, missing data, and out-of-sample distributions. To address the possibility of feedback loops, we must consider the time scale at which these feedbacks reach steady-state: fast timescale feedback loops can be addressed with the chain graph interpretation of SCMs [59] [60]; intermediate timescale feedbacks can be addressed with non-recursive structural causal models [5]; slow timescale feedback loops can be handled by unrolling the structure of the SCM as is done with dynamic Bayesian networks [61], or simply by representing the entire feedback loop as a biological process, as we did with IL6-AMP. In the case of model misspecification, we will investigate the ability of counterfactual inference to improve the estimation [43]. For missing data, we can leverage causal inference recoverability algorithms that have been published recently [62], and for handling out-of-sample distributions, we can leverage recent results applying causal inference to the problem of external validity [63]. Future work will focus on addressing these threats to validity when applied to real biological data.

## ACKNOWLEDGMENTS

This work was supported by funds from the PNNL Mathematics and Artificial Reasoning Systems Laboratory Directed Research and Development Initiative. Knowledge curation environments were provided by BioDati.com and Causaly.com. We would also like to acknowledge Jessica Stothers and Rose Glavin at CoronaWhy.org and Marek Ostaszewski at the COVID-19 Disease Map Initiative for providing valuable feedback about the IL6-AMP model.

## REFERENCES

- [1] A. Pezeshki, I. G. Ovsyannikova, B. A. McKinney, G. A. Poland, and R. B. Kennedy, "The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines." *Expert Review of Vaccines*, vol. 18, p. 253, 2019.
- [2] M. Pedragosa, G. Riera, V. Casella, A. Esteve-Codina, Y. Steuerman, C. Seth, G. Bocharov, S. Heath, I. Gat-Viks, J. Argilaguet, and A. Meyerhans, "Linking cell dynamics with gene coexpression networks to characterize key events in chronic virus infections," *Frontiers in Immunology*, vol. 10, p. 1002, 2019.
- [3] V. K. Nguyen, F. Klawonn, R. Mikolajczyk, and E. A. Hernandez-Vargas, "Analysis of practical identifiability of a viral infection model," *Plos One*, vol. 11, p. e0167568, 2016.
- [4] A. Arazi, W. F. Pendergraft, R. M. Ribeiro, A. S. Perelson, and N. Hacohen, "Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches," *Seminars in Immunology*, vol. 25, p. 193, 2013.
- [5] J. Pearl, *Causality: Models, Reasoning and Inference*. Cambridge, MA, USA., 2013.
- [6] J. Peters, D. Janzing, and B. Schölkopf, *Elements of Causal Inference: Foundations and Learning Algorithms*. MIT press, 2017.
- [7] J. F. Allen, M. Swift, and W. De Beaumont, "Deep semantic analysis of text," *Proceedings of the 2008 Conference on Semantics in Text Processing*, vol. 1, p. 343, 2008.
- [8] D. D. McDonald, "Issues in the Representation of Real Texts: The Design of Krisp," *Natural Language Processing and Knowledge Representation*, p. 77, 2000.
- [9] M. A. Valenzuela-Escárcega, O. Babur, G. Hahn-Powell, D. Bell, T. Hicks, E. Noriega-Atala, X. Wang, M. Surdeanu, E. Demir, and C. T. Morrison, "Large-scale automated machine reading discovers new cancer-driving mechanisms," *Database*, vol. 2018, p. 1, 2018.
- [10] B. M. Gyori, J. A. Bachman, K. Subramanian, J. L. Muhlich, L. Galescu, and P. K. Sorger, "From word models to executable models of signaling networks using automated assembly," *Molecular Systems Biology*, vol. 13, 2017.
- [11] C. T. Hoyt, D. Domingo-Fernández, R. Aldisi, L. Xu, K. Kolpeja, S. Spalek, E. Wollert, J. Bachman, B. M. Gyori, P. Greene, and M. Hofmann-Apitius, "Re-curation and rational enrichment of knowledge graphs in Biological Expression Language," *Database*, vol. 2019, 2019.
- [12] E. G. Cerami, B. E. Gross, E. Demir, I. Rodchenkov, O. Babur, N. Anwar, N. Schultz, G. D. Bader, and C. Sander, "Pathway Commons, a web resource for biological pathway data," *Nucleic Acids Research*, vol. 39, p. 685, 2011.
- [13] A. Fabregat, S. Jupe, L. Matthews, K. Sidiropoulos, M. Gillespie, P. Garapati *et al.*, "The Reactome pathway knowledgebase," *Nucleic Acids Research*, vol. 46, p. D649, 2018.
- [14] M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, and K. Morishima, "KEGG: New perspectives on genomes, pathways, diseases and drugs," *Nucleic Acids Research*, vol. 45, p. D353, 2017.
- [15] L. Peretto, L. Briganti, A. Calderone, A. C. Perpetuini, M. Ianuccelli, F. Langone, L. Licata, M. Marinkovic, A. Mattioni, T. Pavlidou, D. Peluso, L. L. Petrilli, S. Pirró, D. Posca, E. Santonico, A. Silvestri, F. Spada, L. Castagnoli, and G. Cesareni, "SIGNOR: A database of causal relationships between biological entities," *Nucleic Acids Research*, vol. 44, p. D548, 2016.
- [16] D. N. Slenter, M. Kutmon, K. Hanspers, A. Riutta, J. Windsor, N. Nunes *et al.*, "WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research." *Nucleic Acids Research*, vol. 46, p. D661, 2018.
- [17] E. Demir, M. P. Cary, S. Paley, K. Fukuda, C. Lemer, I. Vastrik *et al.*, "The BioPAX community standard for pathway data sharing," *Nature Biotechnology*, vol. 28, p. 1308, 2010.
- [18] M. Hucka, F. T. Bergmann, A. Dräger, S. Hoops, S. M. Keating, N. Le Novère, C. J. Myers, B. G. Olivier, S. Sahle *et al.*, "The Systems Biology Markup Language (SBML): language specification for level 3 version 2 core," *Journal of Integrative Bioinformatics*, vol. 15, 2018.
- [19] N. Le Novère, M. Hucka, H. Mi, S. Moodie, F. Schreiber, A. Sorokin, E. Demir, K. Wegner, M. I. Aladjem, S. M. Wimalaratne *et al.*, "The systems biology graphical notation," *Nature Biotechnology*, vol. 27, p. 735, 2009.
- [20] T. Slater, "Recent advances in modeling languages for pathway maps and computable biological networks," *Drug Discovery Today*, vol. 19, p. 193, 2014.
- [21] P. Machamer, L. Darden, and C. F. Craver, "Thinking about mechanisms," *Philosophy of Science*, vol. 67, p. 1, 2000.
- [22] Y. Li, J. Roberts, Z. AkhavanAghdam, and N. Hao, "Mitogen-activated protein kinase (MAPK) dynamics determine cell fate in the yeast mating response," *The Journal of Biological Chemistry*, vol. 292, p. 20354, 2017.
- [23] L. Chen, R. Wang, C. Li, and K. Aihara, *Modeling Biomolecular Networks in Cells: Structures and Dynamics*. Springer Science & Business Media, 2010.
- [24] D. Gratie, B. Iancu, and I. Petre, "ODE analysis of biological systems," in *International School on Formal Methods for the Design of Computer, Communication and Software Systems*, 2013, p. 29.
- [25] F. Bianconi, E. Baldelli, V. Ludovini, L. Crino, A. Flacco, and P. Valigi, "Computational model of EGFR and IGF1R pathways in lung cancer: a systems biology approach for translational oncology," *Biotechnology Advances*, vol. 30, p. 142, 2012.
- [26] E. K. Kim and E.-J. Choi, "Pathological roles of MAPK signaling pathways in human diseases," *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1802, p. 396, 2010.
- [27] R. Ness, K. Paneri, and O. Vitek, "Integrating Markov processes with structural causal modeling enables counterfactual inference in complex systems," in *Advances in Neural Information Processing Systems*, 2019, p. 14211.
- [28] K. Paneri, "Integrating markov process and structural causal models enables counterfactual inference in complex systems," 2019.
- [29] D. T. Gillespie, "Exact stochastic simulation of coupled chemical reactions," *The Journal of Physical Chemistry*, vol. 81, p. 2340, 1977.
- [30] S. K. Jha and C. J. Langmead, "Exploring behaviors of stochastic differential equation models of biological systems using change of measures," *BMC Bioinformatics*, vol. 13, p. S8, 2012.
- [31] U. Alon, *An Introduction to Systems Biology: Design Principles of Biological Circuits*. CRC press, 2019.
- [32] S. Bongers and J. M. Mooij, "From random differential equations to structural causal models: the stochastic case," in *Proceedings of Uncertainty in Artificial Intelligence*, 2019.
- [33] M. Jerrum, A. Sinclair, and D. S. Hochbaum, "The Markov chain Monte Carlo method," *Approximation Algorithms for NP-hard Problems*, 1997.

- [34] A. E. Gelfand, "Gibbs sampling," *Journal of the American statistical Association*, vol. 95, p. 1300, 2000.
- [35] M. D. Hoffman and A. Gelman, "The No-U-Turn sampler: adaptively setting path lengths in Hamiltonian Monte Carlo," *Journal of Machine Learning Research*, vol. 15, p. 1593, 2014.
- [36] M. D. Hoffman, D. M. Blei, C. Wang, and J. Paisley, "Stochastic variational inference," *The Journal of Machine Learning Research*, vol. 14, p. 1303, 2013.
- [37] T. Blom, S. Bongers, and J. M. Mooij, "Beyond structural causal models: Causal constraints models," in *Proceedings of the 35th Conference on Uncertainty in Artificial Intelligence*, 2019.
- [38] S. Madan, J. Szostak, R. Komandur Elayavilli, R. T.-H. Tsai, M. Ali, L. Qian, M. Rastegar-Mojarad, J. Hoeng, and J. Fluck, "The extraction of complex relationships and their conversion to biological expression language (BEL) overview of the BioCreative VI (2017) BEL track." *Database: the Journal of Biological Databases and Curation*, vol. 2019, 2019.
- [39] C. T. Hoyt, D. Domingo-Fernández, S. Mubeen, J. M. Llaó, A. Konotopez, C. Ebeling, C. Birkenbihl, O. Muslu, B. English, S. Müller, M. P. de Lacerda, M. Ali, S. Colby, D. Türei, N. Palacio-Escat, and M. Hofmann-Apitius, "Integration of structured biological data sources using biological expression language," *BioRxiv*, 2019.
- [40] C. T. Hoyt, A. Konotopez, C. Ebeling, and J. Wren, "PyBEL: a computational framework for biological expression language." *Bioinformatics*, vol. 34, p. 703, 2018.
- [41] H. Mi, F. Schreiber, S. Moodie, T. Czauderna, E. Demir, R. Haw, A. Luna, N. Le Novère, A. Sorokin, and A. Villéger, "Systems Biology Graphical Notation: Activity Flow language Level 1 Version 1.2." *Journal of Integrative Bioinformatics*, vol. 12, p. 265, 2015.
- [42] D. J. Rezende, S. Mohamed, and D. Wierstra, "Stochastic backpropagation and approximate inference in deep generative models," *arXiv:1401.4082*, 2014.
- [43] R. Ness, K. Paneri, and O. Vitek, "Integrating Markov processes with structural causal modeling enables counterfactual inference in complex systems," in *Advances in Neural Information Processing Systems*, 2019, p. 14234.
- [44] "BioDati, inc." [Online]. Available: <https://studio.covid19.biodati.com/>
- [45] E. Bingham, J. P. Chen, M. Jankowiak, F. Obermeyer, N. Pradhan, T. Karaletsos, R. Singh, P. Szerlip, P. Horsfall, and N. D. Goodman, "Pyro: Deep Universal Probabilistic Programming," *Journal of Machine Learning Research*, 2018.
- [46] Z. S. Ulhaq and G. V. Soraya, "Interleukin-6 as a potential biomarker of COVID-19 progression." *Medecine et Maladies Infectieuses*, vol. 50, p. 382, 2020.
- [47] T. Hirano and M. Murakami, "COVID-19: A new virus, but a familiar receptor and cytokine release syndrome." *Immunity*, vol. 52, p. 731, 2020.
- [48] M. Murakami and T. Hirano, "The pathological and physiological roles of IL-6 amplifier activation." *International Journal of Biological Sciences*, vol. 8, p. 1267, 2012.
- [49] H. Ogura, M. Murakami, Y. Okuyama, M. Tsuruoka, C. Kitabayashi, M. Kanamoto, M. Nishihara, Y. Iwakura, and T. Hirano, "Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction," *Immunity*, vol. 29, p. 628, 2008.
- [50] V. Oldfield, S. Dhillon, and G. L. Plosker, "Tocilizumab: a review of its use in the management of rheumatoid arthritis." *Drugs*, vol. 69, p. 609, 2009.
- [51] C. Zhang, Z. Wu, J.-W. Li, H. Zhao, and G.-Q. Wang, "Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist Tocilizumab may be the key to reduce mortality," *International Journal of Antimicrobial Agents*, vol. 55, p. 105954, 2020.
- [52] E. A. Coomes and H. Haghbayan, "Interleukin-6 in COVID-19: A systematic review and meta-analysis," *medRxiv*, 2020.
- [53] X. Xu, M. Han, T. Li, W. Sun, D. Wang, B. Fu, Y. Zhou, X. Zheng, X. L. Y. Yang, X. Zhang, A. Pan, and H. Wei, "Effective Treatment of Severe COVID - 19 Patients with Tocilizumab," *PNAS*, vol. 117, p. 10970, 2020.
- [54] K. E. R. Soetaert, T. Petzoldt, and R. W. Setzer, "Solving differential equations in R: package deSolve," *Journal of Statistical Software*, vol. 33, 2010.
- [55] D. Wilkinson, "Package smsfb," 2018.
- [56] L. Lu Wang, K. Lo, Y. Chandrasekhar, R. Reas, J. Yang, D. Eide, K. Funk, R. Kinney, Z. Liu, W. Merrill, P. Mooney, D. Murdick, D. Rishi, J. Sheehan, Z. Shen, B. Stilson, A. D. Wade, K. Wang, C. Wilhelm, B. Xie, D. Raymond, D. S. Weld, O. Etzioni, and S. Kohlmeier, "CORD-19: The covid-19 open research dataset." *arXiv*, 2020.
- [57] A. Liu, P. Trairatphisan, E. Gjerga, A. Didangelos, J. Barratt, and J. Saez-Rodriguez, "From expression footprints to causal pathways: contextualizing large signaling networks with CAR-NIVAL," *Systems Biology and Applications*, vol. 5, p. 1, 2019.
- [58] S. Tikka and J. Karvanen, "Identifying causal effects with theR packagecausaleffect," *Journal of Statistical Software*, vol. 76, p. 1, 2017.
- [59] S. L. Lauritzen and T. S. Richardson, "Chain graph models and their causal interpretations," *Journal of the Royal Statistical Society: Series B*, vol. 64, p. 321, 2002.
- [60] E. Sherman and I. Shpitser, "Identification and estimation of causal effects from dependent data." *Advances in Neural Information Processing Systems*, vol. 2018, p. 9446, 2018.
- [61] D. Koller and N. Friedman, *Probabilistic Graphical Models: Principles and Techniques - Adaptive Computation and Machine Learning*. The MIT Press, 2009.
- [62] R. Nabi, R. Bhattacharya, and I. Shpitser, "Full law identification in graphical models of missing data: Completeness results," *arXiv*, 2020.
- [63] E. Bareinboim and J. Pearl, "Causal inference and the data-fusion problem." *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113, p. 7345, 2016.